Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide

被引:0
|
作者
Lowman, E. [1 ]
Hardigan, P. [2 ]
Unger, N. [3 ]
Lee, N. [1 ]
机构
[1] Midland Res Grp, Oakland Pk, FL USA
[2] Nova Southeastern Univ, Dr Kiran C Patel Coll Allopath Med, Ft Lauderdale, FL 33314 USA
[3] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
P077
引用
收藏
页码:75 / 75
页数:1
相关论文
共 50 条
  • [41] Breakthrough HIV viraemia on bictegravir/emtricitabine/tenofovir alafenamide in the third trimester of pregnancy
    Miller, Caragh
    Giguere, Pierre
    Mcguinty, Michaeline
    Angel, Jonathan Benjamin
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2390 - 2391
  • [42] Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Emma D. Deeks
    [J]. Drugs, 2019, 79 : 687 - 687
  • [43] Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
    Pohlman, F. Will
    McGee, Kara S.
    McKellar, Mehri S.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (08):
  • [44] Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties
    Ferrandez, Javier Sanchez-Rubio
    Garcia, Angel Lopez
    Alonso-Vega, Gabriel Gaspar
    Gonzalez, Alberto Onteniente
    Garcia, Teresa Molina
    [J]. ANNALS OF PHARMACOTHERAPY, 2021, 55 (04) : 556 - 557
  • [46] Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV A Cohort Study
    Surial, Bernard
    Mugglin, Catrina
    Calmy, Alexandra
    Cavassini, Matthias
    Gunthard, Huldrych F.
    Stockle, Marcel
    Bernasconi, Enos
    Schmid, Patrick
    Tarr, Philip E.
    Furrer, Hansjakob
    Ledergerber, Bruno
    Wandeler, Gilles
    Rauch, Andri
    [J]. ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : 758 - +
  • [47] Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen
    Guillen, Santiago Moreno
    Martorell, Claudia
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason
    Martin, Hal
    Baeten, Jared
    Pozniak, Anton
    [J]. HIV MEDICINE, 2023, 24 : 21 - 22
  • [48] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Cohen, Calvin
    Elion, Richard
    Ruane, Peter
    Shamblaw, David
    DeJesus, Edwin
    Rashbaum, Bruce
    Chuck, Steven L.
    Yale, Kitty
    Liu, Hui C.
    Warren, David R.
    Ramanathan, Srinivasan
    Kearney, Brian P.
    [J]. AIDS, 2011, 25 (06) : F7 - F12
  • [49] Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART
    Okochi, Hideaki
    Louie, Alexander
    Nhi Phung
    Zhang, Kevin
    Tallerico, Regina M.
    Kuncze, Karen
    Spinelli, Matthew A.
    Koss, Catherine A.
    Benet, Leslie Z.
    Gandhi, Monica
    [J]. DRUG TESTING AND ANALYSIS, 2021, 13 (07) : 1354 - 1370
  • [50] Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
    Xia, Huan
    Huang, Xiao-Jie
    Hu, Yue
    Gao, Li-Ying
    Wu, Yue
    Wu, Hao
    Yan, Zhong-Fang
    Ma, Ping
    [J]. CHINESE MEDICAL JOURNAL, 2021, 134 (23) : 2850 - 2856